David Drutz - 18 Nov 2022 Form 4 Insider Report for Altimmune, Inc. (ALT)

Role: Director
Signature: /s/ Richard Eisenstadt, as Attorney-in-Fact
Issuer symbol: ALT
Transactions as of: 18 Nov 2022
Net transactions value: +$334
Form type: 4
Filing time: 21 Nov 2022, 15:05:18 UTC
Previous filing: 30 Sep 2022
Next filing: 27 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALT	Common Stock, par value $0.0001	Options Exercise	$334	+139	+0.69%	$2.40	20,151	18 Nov 2022	Direct
holding	ALT	Common Stock, par value $0.0001						333	18 Nov 2022	See Footnote	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALT	Stock Options (option to buy)	Options Exercise	$0	-139	-100%	$0.000000^*	0	18 Nov 2022	Common Stock, par value $0.0001	139	$2.40	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President.
F2	This option was previously reported as covering 4,178 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split that occurred on September 13, 2018.
F3	This option is fully vested and exercisable as of the date hereof.